We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
A picture of Andrew Mahan

Andrew Mahan profile page

Principal Scientist/MS Group Leader, Cell & Developability Sciences Janssen Pharmaceutical Companies of Johnson & Johnson


Got a Question for Andrew Mahan?

Get in touch using the contact form linked here and we’ll get back to you shortly



Published Content
Total: 1
Advanced Technology To Accelerate Development of Next-Generation Biotherapeutics content piece image
Webinar

Advanced Technology To Accelerate Development of Next-Generation Biotherapeutics

Biopharmaceutical companies are transitioning from the development of standard monoclonal antibody therapies to more intricate antibody structures and new genetic medicines. Not only are these molecules more complex, but scientists are also under tremendous pressure to understand molecular liabilities sooner and close the developability gap in a much shorter time frame.
Advertisement
Advertisement
Advertisement
Decoratvive background images
Never miss a story
with the Breaking Science News daily newsletter